

# Market Announcement

19 November 2020

---

## Incannex Healthcare Limited (ASX: IHL) – Trading Halt

### Description

The securities of Incannex Healthcare Limited ('IHL') will be placed in trading halt at the request of IHL, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 23 November 2020 or when the announcement is released to the market.

### Issued by

**Melissa Kostopoulos**

Compliance Adviser, Listings Compliance (Melbourne)

Melissa Kostopoulos  
Compliance Advisor, Listings Compliance (Melbourne)  
ASX Limited  
Level 4, North Tower, Rialto  
525 Collins Street  
Melbourne VIC 3000

By email: [melissa.kostopoulos@asx.com.au](mailto:melissa.kostopoulos@asx.com.au)  
[tradinghaltsmelbourne@asx.com.au](mailto:tradinghaltsmelbourne@asx.com.au)

Dear Melissa,

## Trading Halt Request

Pursuant to ASX Listing Rule 17.1, Incannex Healthcare Limited ("the Company") (ASX code: IHL) requests that an immediate trading halt be put on its securities, pending an ASX announcement by the Company regarding the results of an in vivo study relevant to the development of IHL-675A and its corresponding FDA regulatory strategy.

The Company advises the trading halt is to last until the commencement of trade on Monday 23<sup>rd</sup> November 2020 or the release of the announcement.

The Company confirms that is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.

On behalf of the IHL Board of Directors,



Glenn Fowles  
Company Secretary